KIT and gastrointestinal stromal tumor: Although the demonstration of c-kit (CD117) immunoreactivity represents the gold standard for diagnosis of GIST (it's also considered as an eligibility criterion for Imatinib Masylate therapy) [2,3] approximately 5% of histologocally suspected GIST are CD117 negative [1,17,18].